CYTOKINETICS INC (CYTK) Stock
2 members of Congress disclosed 5 trades in CYTK since 2025: 4 purchases and 1 sale, most recently Gilbert Cisneros (purchase, Sep 29, 2026). 6 of the hedge funds AlphaScala tracks reported CYTK in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Point72's at $135.26M. Company insiders reported 0 open-market buys and 17 sales on SEC Form 4 in the 90 days to Nov 5, 2026.
Which members of Congress traded CYTOKINETICS INC (CYTK)?
Most recent: Gilbert Cisneros (purchase, Sep 29, 2026); records start Jun 11, 2025.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Gil Cisneros D-CA · House | 2026-09-29 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2026-06-30 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2025-10-09 | purchase | $1k – $15k |
| Lisa McClain R-MI · House | 2025-06-17 | sale | $1k – $15k |
| Lisa McClain R-MI · House | 2025-06-11 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026.
See all CYTK political trades →Which hedge funds own CYTK?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Point72 Steve Cohen | 1.59M | $135.26M | +154% |
| D.E. Shaw David Shaw | 1.05M | $89.29M | +48% |
| Citadel Ken Griffin | 641K | $54.60M | -42% |
| Marshall Wace | 451K | $38.46M | -31% |
| Millennium Management Israel Englander | 110K | $9.35M | +12% |
| Blackstone | 4K | $309.2K | +8% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are CYTOKINETICS INC insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Nov 3, 26 | Malik Fady Ibraham | EVP Research & Development | SELL | 3.5K | $220K |
| Nov 2, 26 | Blum Robert I | President & CEO | SELL | 7.5K | $471K |
| Oct 20, 26 | Malik Fady Ibraham | EVP Research & Development | SELL | 3.5K | $224K |
| Oct 12, 26 | Blum Robert I | President & CEO | SELL | 7.5K | $472K |
| Oct 6, 26 | Malik Fady Ibraham | EVP Research & Development | SELL | 3.5K | $215K |
| Sep 28, 26 | Blum Robert I | President & CEO | SELL | 7.5K | $491K |
| Sep 22, 26 | Malik Fady Ibraham | EVP Research & Development | SELL | 3.5K | $239K |
| Sep 15, 26 | Blum Robert I | President & CEO | SELL | 97.9K | $6.8M |
| Sep 15, 26 | Landry Robert E | Director | SELL | 1.0K | $72K |
| Sep 14, 26 | Blum Robert I | President & CEO | SELL | 7.5K | $551K |
SEC Form 4 filings as of Nov 5, 2026
See cluster-buy signals across all tickers →CYTK price chart
Powered by TradingViewWhat does CYTOKINETICS INC do?
Cytokinetics, Incorporated is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors. These small-molecule therapies target debilitating diseases where muscle performance is compromised or declining, including amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, hypertrophic cardiomyopathy, and chronic obstructive pulmonary disease. By specifically engineering compounds to enhance muscle function and contractility, Cytokinetics addresses impaired muscle function in cardiovascular and neuromuscular conditions. The company advances muscle-directed investigational medicines aimed at improving health outcomes for patients with serious diseases of cardiac and skeletal muscle dysfunction. Founded in 1997 and headquartered in South San Francisco, California, Cytokinetics leverages expertise in muscle biology to build a pipeline of sarcomere-directed therapies, positioning it as a key player in specialized biopharmaceutical innovation for muscle-related disorders.